Abstract

Patient specific therapy is emerging as an important possibility for many cancer patients. However, to identify such therapies it is essential to determine the genomic and transcriptional alterations present in one tumor relative to control samples. This presents a challenge since use of a single sample precludes many standard statistical analysis techniques. We reasoned that one means of addressing this issue is by comparing transcriptional changes in one tumor with those observed in a large cohort of patients analyzed by The Cancer Genome Atlas (TCGA). To test this directly, we devised a bioinformatics pipeline to identify differentially expressed genes in tumors resected from patients suffering from the most common malignant adult brain tumor, glioblastoma (GBM). We performed RNA sequencing on tumors from individual GBM patients and filtered the results through the TCGA database in order to identify possible gene networks that are overrepresented in GBM samples relative to controls. Importantly, we demonstrate that hypergeometric-based analysis of gene pairs identifies gene networks that validate experimentally. These studies identify a putative workflow for uncovering differentially expressed patient specific genes and gene networks for GBM and other cancers.

Highlights

  • Glioblastoma multiforme (GBM) is the most common malignant adult brain tumor, comprising 15.6% of all central nervous system tumors [1]

  • In this report we identified a patient specific list of differentially expressed genes (DEGs), which can be used as input for multiple types of analyses including gene co-expression networking

  • Identifying genes differentially expressed in GBM via RNA sequencing and The Cancer Genome Atlas (TCGA) enrichment We performed RNA sequencing on 2 GBM tumors (GBM17 and GBM31) and 2 epilepsy control tissues (Control16 and Control34) using the Illumina HiSeq platform

Read more

Summary

Introduction

Glioblastoma multiforme (GBM) is the most common malignant adult brain tumor, comprising 15.6% of all central nervous system tumors [1]. Recent developments in oncogenomics point to a highly heterogeneous genomic landscape in GBM [4, 5]. This heterogeneity necessitates genome and transcriptome analyses of each tumor individually in the hopes of discovering patient specific therapies [6]. Discovering patient–specific transcriptional alterations is difficult given the low patient sample size (n51). This is especially true when using RNA sequencing given the discordance of different RNA-Seq alignment and analysis algorithms when sample size is small [7]

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.